Recurrent Cystine Stones Despite Maximal Hydration and Alkalinization
A genetic stone former whose fluid intake and urine logs already look close to ideal, and a question about whether the gap is really conservative therapy failing, or one overnight window it hasn't been reaching.
Tomás V., a 28-year-old software engineer, was diagnosed with cystinuria at fourteen after his second stone, and has spent most of his adult life managing a genetic condition that has nothing to do with the mostly sedentary job he sits at all day — his parents both carry a single copy of the mutated gene without ever forming a stone themselves, something he only fully understood once his own diagnosis sent the whole family for testing. Training for his first marathon this year has, if anything, made his hydration habits better than they've ever been — his tracked fluid logs show a consistent intake well above three liters daily — which is part of what makes his sixth stone episode this month feel, to him, like proof that nothing he does matters.
His biallelic SLC3A1 mutation means his kidneys cannot properly reabsorb cystine, and above a concentration threshold that varies with urine pH, it crystallizes into stones — a mechanism conservative therapy targets from two directions, high fluid intake to dilute the urine and alkalinization with potassium citrate to raise pH toward the range where cystine stays soluble. His mean urine pH on citrate is 6.6, close to target, but a closer look at his actual log shows real variability underneath that average: several overnight readings sit below 6.0, hours where his last citrate dose has worn off and cystine solubility drops sharply before his morning dose restores it — a gap his marathon training schedule may be quietly widening, since his long training runs fall in exactly the hours his last dose is furthest from covering. A repeat cystine supersaturation index remains persistently elevated despite everything he's already doing right. The American Urological Association's medical-management guideline recommends adding a thiol-based binding agent such as tiopronin specifically for cystinuria patients who continue forming stones despite maximized fluid intake and alkalinization — a threshold his six episodes and elevated supersaturation index appear to meet, though nobody in the room has yet looked closely enough at his dosing schedule to be certain conservative therapy has actually been maximized, rather than merely averaging well.
At the stone-clinic follow-up, reviewing the urine log
Six episodes despite fluid logs this consistent is the picture the AUA guideline describes when it recommends adding a thiol agent like tiopronin — conservative therapy failing despite genuine adherence, not despite poor effort. His supersaturation index is still elevated. I think we're past the point where more conservative measures alone are likely to change his trajectory.
Before we call conservative therapy maximized, I looked at his actual urine pH log rather than just the mean. It's 6.6 on average, which looks fine, but several overnight readings sit below 6.0 — his last citrate dose is wearing off hours before the next one, and cystine solubility drops sharply in that range. Adding a bedtime dose to cover that trough is a real, specific fix we haven't tried, and it's a much lower-burden step than tiopronin.
You're right his mean pH looks good — I hadn't looked at the diurnal pattern, and that's a real gap in what we called 'maximized' conservative therapy. I'd support trying the redosing fix first. But six episodes in someone with biallelic, early-onset disease is a genuinely aggressive phenotype, and I don't want an open-ended trial — I'd want a defined recheck point and an explicit trigger for starting tiopronin if the fix doesn't move his supersaturation index.
Agreed: redose potassium citrate with an added bedtime dose to cover the overnight trough, and repeat a full 24-hour urine collection with cystine supersaturation index in eight weeks.
Not agreed: whether tiopronin is probably inevitable regardless of the dosing fix, given how aggressive his phenotype has already proven itself to be. The tiopronin-focused voice held that delaying further risks another symptomatic stone in the meantime, a real difference in how much weight each voice puts on trying one more conservative step versus his own six-episode track record.